@C4BI
AI transformation at the speed of a bullet train!
Innovation in Pharma has been facilitated by advances in
technical fields, with AI supporting the latest and fastest developing
computing capabilities.
ICT industry investment in AI has increased dramatically and
is fuelling AI hype, seeking use cases that fit AI capabilities. This has
created fear-of-missing-out and fear-of-falling-behind, forcing businesses to
reassess their innovation strategies and prioritize AI adoption. Pharma is not
an exception.
- Pharma
organizations are exploring possible benefits from fast-advancing
technologies and grappling with the issues of the AI technology validation
and the AI output and process verification to ensure safe AI use.
- Regulatory
bodies are revisiting compliance requirements and legal obligations,
aiming to provide implementation guidance. However, the AI development
pace requires ongoing monitoring and revision that are currently lacking
and leaving organizations to figure out on their own a safe way of using
latest AI advances.
- AI
complexity and lack of knowledge are forcing Pharma organizations to make
decisions on a trial-and-error basis and, in the process, risk
non-compliance.
- The
AI for Pharma Consortium is an efficient way for the organizations to find
a solid common ground, to align and coordinate adoption of AI approaches,
and remain compliant with regulations while pursing AI based
innovation.
For details and a chat please contact natasa@cfbi.com or ceo@cfbi.com
